Abstract
A synthesized and promising biologically hypoglycemic compound 5,6-Dichloro-2-[2-(pyridin-2-yl)ethyl]isoindoline-1,3-dione (5e) was studied for its binding to a model protein (bovine serum albumin; BSA) by spectroscopic and molecular simulation approaches. Fluorescence studies revealed that 5e quenched BSA’s intrinsic fluorescence by static quenching. The experiments were performed at three different temperatures and the quenching constants and binding constants were evaluated. Stern-Volmer constant (Ksv) values decreased from 1.36 × 104 to 1.20 × 104 as the temperature increased suggesting static quenching involvement in the interaction. Decreased binding constants from 1.70 × 104 to 4.57 × 103 at higher temperatures indicated instability of the complex at rising temperatures. Site I (subdomain IIA) of BSA was found to interact with 5e. The thermodynamic results showed the binding interaction was spontaneous and enthalpy driven. The secondary structure alterations in BSA due to interaction with 5e were studied by UV–visible, synchronous fluorescence, and three-dimensional fluorescence spectra. The results indicate the 5e binds effectively to the BSA and thus, this study can be useful in further exploring the pharmacokinetics and pharmacodynamics of 5e.
Keywords: BSA, Thermodynamics, Docking, Fluorescence quenching, Spectroscopy
1. Introduction
Amongst the biomolecules the proteins are the most important and are involved in numerous biological processes. Protein content in biological fluids is of diagnostic value for determination of several diseased conditions and is also of an immense value in the chemical investigations (Kandagal et al., 2006, Zhu et al., 2007, Suryawanshi et al., 2016). The protein and drug interaction, protein structure and functional changes on biological performance is of great interest to the researchers (Peters, 1996, He and Carter, 1992).
In the transportation and disposition of drugs in biological system serum albumin present in the blood plasma plays a major role. The extensive study of BSA as model protein for these interaction is because of its structural homology to the human serum albumin (Mote et al., 2010, Wang et al., 2007). Structurally BSA consists of three homologous domains and each of these domains consist of two sub-domains namely sub-domain IA, IB, IIA, IIB, IIIA, and IIIB. These sub-domains of BSA are involved in binding the endogenous and/or exogenous ligands. The ligand binding sites of BSA are located in the hydrophobic cavities of sub-domains IIA and IIIA (He and Carter, 1992).
The biological activities of N-substituted phthalimides is well established (Cullen, 2000, Krauss, 1998, Rubins, 2000, Rubins and Robins, 2000). The anti-hyperlipidemic and anti-diabetic potential of these compounds have been explored (Kim et al., 2006, Zimmet et al., 2001) The mechanism of hypolipidemic activity of N-substituted phthalimides is supposed to be due to their inhibitory activity against acetyl-CoA (Kim et al., 2006, Betteridge, 1984). The studied compound 5e (Fig. 1) (Alaa et al., 2011) was found to lower the serum glucose in diabetic rate by 55% and the reduction was more than the standard drug glibenclamide which showed only 51% reduction in the serum glucose levels of diabetic rats. Further, 5e decreased the cholesterol and triglyceride levels more efficiently than the positive control glibenclamide (Alaa et al., 2011).
Fig. 1.
Chemical structure of 5,6-Dichloro-2-[2-(pyridin-2-yl)ethyl]isoindoline-1,3-dione (5e).
Pharmacokinetic and pharmacodynamics of a drug is dependent on the drug-protein interaction. Fluorescence technique are particularly used to explore ligand protein interactions (Chi et al., 2010, Wani et al., 2017a, Wani et al., 2017b, Wani et al., 2017c, Wani et al., 2018a). The affinity of 5e for BSA was investigated in this study and thus, explore the carrier role of BSA for 5e under physiological conditions. The binding studies are helpful in understanding the interaction mechanism and designing of suitable ligands. In addition to the fluorescence quenching study, conformational changes in the BSA post interaction were also studied by UV–visible spectroscopy, synchronous fluorescence (SF), and three-dimensional spectroscopy. Different temperatures were used to carry out the binding studies and evaluate the involved thermodynamic processes. Molecular docking studies were also carried out for the ligand and the BSA protein and the obtained results were related to the spectroscopic experimental results.
2. Materials and methods
2.1. Materials
The materials and their procuring sources were as follows: Fatty acid free BSA (Sigma Aldrich; USA); Ibuprofen and phenylbutazone (National Scientific Company; KSA). The 5e was synthesized (Alaa et al., 2011) in synthetic chemistry laboratory of Pharmaceutical Chemistry Department; College of Pharmacy; King Saud University. The BSA, 5e, ibuprofen and phenylbutazone stocks were prepared in phosphate buffer (pH 7.4). The water used for buffer preparation was from Elga Purelab (Elga Lab Water UK). Materials of analytical purity were used for the analysis.
2.2. Instrumentation
The fluorescence emission spectra were recorded at three temperatures 298, 305 and 310 K using JASCO spectrofluorometer. A slit width of 5 nm was used for attaining both excitation and emission spectra. An excitation wavelength of 280 nm and emission wavelength of 300–500 nm was used to obtain the fluorescence spectra. The UV–vis absorption spectra were recoded using UV-1800 spectrophotometer from Shimadzu (Japan) The spectra were recorded in the range of 200–500 nm.
2.3. Fluorescence spectral and UV–Vis spectral measurement
The fluorescence spectra of BSA and BSA-5e complex were recorded. A fixed concentration of BSA and variable concentrations of 5e were used to record the spectra. Inner filter effect can lead to reduced fluorescence intensity (FI) and therefore need to be corrected. The inner filter effects were corrected with the equation:
| (1) |
The fluorescence (corrected and observed) were represented by Fcor and Fobs respectively. The absorption at the excitation and emission wavelength of 5e were denoted by Aex and Aem.
The UV–Vis spectra were recorded at room temperature (298 K) for the BSA and BSA-5e complex (fixed BSA concentration and increasing 5e concentration).
2.4. Synchronous fluorescence (SF)spectral measurement and site binding studies
SF spectra for 5e and BSA-5e complexes were recorded at room temperature (298 K). The scanning intervals Δλ ((Δλ = λ em − λex) equal to 15 and 60 nm were used to record the spectra. The intervals of Δλ = 15 nm and 60 nm characterize the tyrosine (Tyr) and tryptophan (Trp) residues respectively. Binding site identification for 5e on BSA was carried out using displacement studies for site specific markers phenylbutazone and ibuprofen.
2.5. Molecular docking
Molecular simulation experiments were done to study the BSA-5e-binding interaction. The interaction was studied using Molecular Operating Environment (MOE) software. Naproxen co-crystallized structure of BSA was acquired from protein data bank; pdb code:4OR0 and the 5e structure was drawn within MOE (Zhou et al., 2018, Jiang et al., 2018). BSA consists of two homodimer chains, named as A and B. These studies were conducted using the chain B of the BSA homodimer.
3. Results and discussions
3.1. Fluorescence studies
The amino acid residues Trp and Tyr are primarily responsible for a protein’s intrinsic fluorescence. It has also been observed that a protein ligand interaction usually reduces the fluorescence intensity of the protein and this reduction is ligand concentration dependent. Thus, the protein ligand interaction can be explored with the help of fluorescence quenching studies. (Chu et al., 2010).
The fluorescence spectra were recorded for BSA whose concentration was held constant and the 5e concentration was varied. (Fig. 2). A reduction in FI of BSA occurred post interaction with 5e and got further reduced with increasing 5e concentration suggesting fluorescence quenching. The fluorescence spectra of BSA-5e showed a blue shift indicating that the chromophore in the serum albumin shifted towards a more hydrophobic microenvironment. The involved quenching mechanisms could be either static or dynamic quenching or combined dynamic and static quenching (Feitelson, 1964, Wang et al., 2016, Zhang et al., 2017). These two mechanisms are distinguished from one another based on their dependency on temperature and viscosity (Mater, 2010). At high temperatures large diffusion coefficients are observed in dynamic quenching and are further increased with rise in temperature. However, in static quenching as the temperature increases the stability of protein–ligand complex decreases leading to lower quenching constants. However, in case of combined dynamic and static quenching both collision and complex formation occur with the same quencher.
Fig. 2.
Fluorescence spectra of BSA (1.5 μM) in the presence of 5e at 298 K; (5e concentration (1.49 × 10−6, 2.99 × 10−6, 5.98 × 10−6,1.49 × 10−5, 5.97 × 10−6, 1.79 × 10−5).
3.2. Quenching mechanism analysis
Stern-Volmer equation was used to elucidate the quenching mechanism between BSA and 5e (Lakowicz, 2004).
| (2) |
F and F0 are the FI of BSA in presence and absence of 5e respectively. Ksv represents the Stern -Volmer constant; [Q] Quencher concentration; kq quenching rate constant; τ0 excited state lifetime of fluorophore and is valued 10−8 S for biomolecules (Lakowicz, 2004, Zhao et al., 2010, Wani et al., 2018b, Hu et al., 2010).
Fig. 3A represents the plot between F0/F and 5e at the different temperatures. The plots exhibited a good linear relationship and the results are given in Table 1. The Ksv values decreased at higher temperatures indicating formation of a ground state complex between BSA and 5e. Formation of complex between BSA and 5e infers involvement of static quenching. The maximum achievable value for the dynamic quenching constant for biopolymers is 2 × 1010 LM−1 S−1 (Ware, 1962). The quenching constant values attained were greater than 2 × 1010 LM−1 S−1 as given in Table 1, further indicates the formation of complex and involvement of static quenching between BSA and 5e.
Fig. 3.
The plots for interaction between BSA with 5e at different temperatures [A]: Stern–Volmer Plot, [B]: Binding Constant log [(F0- F)/F] Vs log[Q], [C]: Van’t Hoff Plot, [D]: Binding constant in presence of site markers at 298 K.
Table 1.
KSV and Kq values for the binding interaction of 5e and BSA at different temperatures.
| T(K) | R | Ksv ± SD × 104 (L mol−1) | kq × 1012 (L mol−1 s−1) |
|---|---|---|---|
| 298 | 0.9958 | 1.36 ± 0.025 | 1.36 |
| 305 | 0.9993 | 1.26 ± 0.016 | 1.26 |
| 310 | 0.9973 | 1.20 ± 0.020 | 1.20 |
3.3. Binding constant and binding site
Therapeutic potential of drugs depends on the in-vivo binding potential of these drugs and this ability can influence their stability and toxicity in a therapeutic process. The binding interaction evaluation between BSA and 5e was based on the binding constants calculated from FI data obtained at different temperatures. The free and bound molecular equilibrium is given by the double log regression curve (Zhao et al., 2009, Rabbani et al., 2017a, Rabbani et al., 2017b. The following equation represents this equilibrium:
| (3) |
In the plot log [(F0 − F)/F] Vs log [Q] (Fig. 3B), slope ‘n’ represents stoichiometry of binding and the binding constant Kb is calculated from the intercept (Table 2). Single binding site for 5e present on BSA molecule is inferred from the fact that n is approximately equal to unity. This binding strength determines the ability of the drug to diffuse from the bound protein to its target of action (Rabbani et al., 2014, Colmenarejo et al., 2001). The ligands bind to the protein mostly in a reversible fashion and exhibit the binding affinities ranging from (1–15) × 104 L M−1 (Dufour and Dangles, 2005). The Kb values obtained showed a decrease at higher temperatures indicating instability of BSA-5e complex. Also, the complex formed may be reversible since the binding between BSA and 5e is moderate.
Table 2.
Binding and thermodynamic parameter values for the binding interaction of 5e and BSA at different temperatures.
| T(K) | R | Log Kb ± SD | Kb (L mol−1) | n | ΔG (kJ mol−1) | ΔH (kJ mol−1) | ΔS (J mol−1 K−1) |
|---|---|---|---|---|---|---|---|
| 298 | 0.9887 | 4.23 ± 0.013 | 1.70 × 104 | 0.98 | −26.48 | −172 | −485 |
| 305 | 0.9874 | 3.94 ± 0.016 | 8.71 × 103 | 0.92 | −24.54 | ||
| 310 | 0.9895 | 3.66 ± 0.010 | 4.57 × 103 | 0.87 | −22.11 |
3.4. Binding site identification
The binding site identification of 5e on BSA was carried out by site competition of 5e with site specific markers phenylbutazone and ibuprofen (Rabbani et al., 2018). Phenylbutazone is specific marker for site I whereas, ibuprofen is specific marker for site II of BSA. A reduction in FI of BSA was observed on addition of phenylbutazone and ibuprofen. However, phenylbutazone caused a higher decrease in the fluorescence intensity compared to ibuprofen. The calculated binding constants for BSA-5e, BSA-phenylbutazone-5e, and BSA-ibuprofen-5e were 1.62 × 104, 0.48 × 102 and 0.91 × 103 respectively (Fig. 3D). Lower binding constants were observed for the phenylbutazone and ibuprofen complexes in comparison to the BSA-5e. Site I (phenylbutazone) Sub-domain IIA as the binding site for 5e was concluded from the fact that the decrease in the binding constant was much more than that observed for ibuprofen.
3.5. Synchronous fluorescence (SF) and Three-dimensional (3D) studies
The SF spectroscopy is mostly utilized to characterize and understand the effect of interaction between the protein and ligand. The SF spectroscopy gives information about microenvironment of chromophores present in the protein. The two amino acid residues mainly involved in the fluorescence of proteins are Trp, Tyr, and Phe. The difference Δλ (Δλ = λ em − λex) (Lakowicz, 2004) reflects the spectral characteristics and nature of chromophores. The effect of varied concentrations of 5e addition on the fluorescence quenching of Tyr and Trp residues of BSA at Δλ = 15 and 60 nm respectively was studied. No change was observed in the emission wavelengths at either Δλ = 15 or 60 nm (Fig. 4). Therefore, it is suggested that the amino acid residues Trp and Tyr polarity present in BSA was slightly altered by 5e.
Fig. 4.
Synchronous fluorescence of BSA-5e complex at 298 K [A] Δλ = 15 nm and [B] Δλ = 60 nm.
The 3D fluorescence spectroscopy provides information regarding the configurational changes that might have occurred in the protein after interacting with the ligands (Loyd and Evett, 1977). The 3D data is presented in the (Fig. 5) and the two peaks found were Peak I and Peak II. The Peak I and II were observed at the excitation wavelength of 230 and 280 nm respectively. Peak I is attributed to the pi-pi transition of polypeptides (Rayleigh scattering peak) whereas, Peak II is attributed to the fluorescent amino acid residues present in BSA. Peak II is attributed to the intrinsic fluorescence of tryptophan and tyrosine residues. These amino acid residues are linked to the conformational changes in the peptide backbone that is associated with helix-transformation. Since there was considerable reduction in BSA fluorescence intensity post 5e addition, it was concluded that peptide backbone (tryptophan and tyrosine) was altered. Thus, conformational changes are suggested to have occurred in BSA indicating complex formation between the BSA and 5e.
Fig. 5.
Three-dimensional fluorescence analysis, BSA [A]: BSA-5e Complex [B].
3.6. Thermodynamic studies
The interaction forces that might occur between the proteins and ligands are established with the help of thermodynamic studies. The type of the interaction between protein and the ligand are characterized by their signs and the magnitude of thermodynamic parameters. The following thermodynamic parameters (ΔG°) Gibbs free energy; (ΔH°) change of enthalpy and (ΔS°) change of entropy were explored to identify the interaction forces between 5e and BSA (Ross and Subramanian, 1981). Value of ΔH° > 0 and ΔS° > 0, indicate hydrophobic interaction forces whereas, ΔH°0 < 0 and ΔS°0 < 0 indicate van der Waals forces and hydrogen-bonding. Electrostatic forces are said to be involved in the interaction in case ΔH° < 0 and ΔS° > 0.
Van't Hoff equation was used to calculate the thermodynamic interaction parameters:
| (4) |
where Kb is the binding constant, R is the universal gas constant, T is temperature in kelvins. The slope of the van't Hoff equation gives us the enthalpy change ΔH°. The free energy change is given with the equation:
| (5) |
The thermodynamic parameters were calculated from the van't Hoff plot (Fig. 3C). The thermodynamic results in Table 2 indicate that the interaction between BSA and 5e was spontaneous in nature since, ΔG° attained a negative value. Since both ΔH° and ΔS° were negative and therefore, suggested an enthalpy driven interaction between BSA and 5e.
3.7. UV–vis absorption studies
The UV–vis absorption methodology was used to study the possible BSA structural alterations and BSA and 5e complex (Shi et al., 2018a, Shi et al., 2018b). Spectra for UV-absorption of BSA (1.5 μM) alone and in presence of 5e at room temperature were recorded (Fig. 6). The following 5e concentrations used were (1.49 × 10−6, 2.99 × 10−6, 5.98 × 10−6, 1.49 × 10−5 and 1.79 × 10−5) for the analysis. The UV-absorption spectra display in the range influence of 5e on the absorption spectrum of BSA. The spectrum showed two bands of absorption for BSA and the stronger band occurred at 210 and whereas the weak band occurred at near 280 nm. The 210 nm band characterize conformational structure of the BSA whereas, the 280 nm band characterizes the π → π transition because of aromatic amino acids. An increased absorption intensity was detected at both the band points as the concentration of 5e was increased suggesting formation of complex between BSA and 5e. Further, a redshift was seen at near 210 nm in the absorption spectrum which also indicated complex formation.
Fig. 6.
UV-absorption spectra of BSA and BSA-5e complex.
3.8. Molecular modeling study
The docking was carried out to further ascertain the BSA binding site to bind 5e (Fig. 7). The binding energy of 5e at sub-domain IIA was −26.63 kJ mol−1, and was lower than the binding energy of 5e on sub-domain IIIA (−25.31 kJ mol−1). This indicated the preferred binding site for 5e to be site I of subdomain IIA and the similar results were seen in binding site identification studies. Also, 5e was observed to be inside the hydrophobic cavity of site I; Fig. 7A.
Fig. 7.
[A] Three dimensional representation of the interaction of 5e with BSA. [B] A two dimensional representation of amino acids that surround 5e.
These results clearly help in understanding the fluorescence quenching behavior of BSA emission in presence of 5e (Shi et al., 2018a, Shi et al., 2018b). The docking results are also in agreement with the thermodynamic studies as hydrogen bonds were seen between the Arg-198 and 5e whereas, Pi-H bonds were observed between Arg-194 and Trp-213 residues of BSA (Fig. 7B). The docking results also showed that 5e interacted with hydrophobic amino acids (Ala-209, Val-481, Val-342, Leu-480, Leu-346, Leu-197. Polar amino acid residues (Trp-213, Ser-201, Ser-343) and charged residues (Arg-217, Arg-198, Arg-194, Asp-450) also interacted with 5e. The free binding energy (−26.63 kJ mol−1) from the docking procedures was close to the free binding energy value obtained experimentally (Table 2).
4. Conclusion
Different spectroscopic methods were used for the detailed study of interaction hypoglycemic compound 5e with BSA. Experimental and docking approaches were used to explore this interaction. BSA and 5e formed a complex and static fluorescence quenching mechanism is suggested to be involved in the interaction. The negative Gibbs free energy suggested a spontaneous interaction between BSA and 5e. The thermodynamic results also suggested involvement of hydrogen-bonding in the interaction. Conformational changes were also suggested in the BSA after interaction with 5e. All these results indicate that 5e can bind to serum albumin, thus, this study can be of helpful in further pharmacokinetic development of 5e.
Conflict of interest
There is no conflict of interest over the contents of this article.
Acknowledgments
The authors extend their sincere appreciation to the Deanship of Scientific Research and the Research Center, College of Pharmacy, King Saud University for funding the research project.
Footnotes
Peer review under responsibility of King Saud University.
References
- Alaa A.-M., El-Azab A.S., Attia S.M., Al-Obaid A.M., Al-Omar M.A., El-Subbagh H.I. Synthesis and biological evaluation of some novel cyclic-imides as hypoglycaemic, anti-hyperlipidemic agents. Eur. J. Med. Chem. 2011;46:4324–4329. doi: 10.1016/j.ejmech.2011.07.002. [DOI] [PubMed] [Google Scholar]
- Betteridge J. Diabetes lipids and atherosclerosis. Pract. Diabetes Int. 1984;1:26–30. [Google Scholar]
- Chi Z., Liu R., Teng Y., Fang X., Gao C. Binding of oxytetracycline to bovine serum albumin: spectroscopic and molecular modeling investigations. J. Agric. Food Chem. 2010;58:10262–10269. doi: 10.1021/jf101417w. [DOI] [PubMed] [Google Scholar]
- Colmenarejo G., Alvarez-Pedraglio A., Lavandera J.L. Cheminformatic models to predict binding affinities to human serum albumin. J. Med. Chem. 2001;44:4370–4378. doi: 10.1021/jm010960b. [DOI] [PubMed] [Google Scholar]
- Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am. J. Cardiol. 2000;86:943–949. doi: 10.1016/s0002-9149(00)01127-9. [DOI] [PubMed] [Google Scholar]
- Dufour C., Dangles O. Flavonoid–serum albumin complexation: determination of binding constants and binding sites by fluorescence spectroscopy. Biochim. Biophys. Acta. 2005;1721:164–173. doi: 10.1016/j.bbagen.2004.10.013. [DOI] [PubMed] [Google Scholar]
- Feitelson J. On the mechanism of fluorescence quenching. Tyrosine and similar compounds. J Phys Chem. 1964;68:391–397. [Google Scholar]
- He X.M., Carter D.C. Atomic structure and chemistry of human serum albumin. Nature. 1992;358:209. doi: 10.1038/358209a0. [DOI] [PubMed] [Google Scholar]
- Hu Y.-J., Ou-Yang Y., Dai C.-M., Liu Y., Xiao X.-H. Binding of berberine to bovine serum albumin: spectroscopic approach. Mol. Biol. Rep. 2010;37:3827–3832. doi: 10.1007/s11033-010-0038-x. [DOI] [PubMed] [Google Scholar]
- Jiang T.Y., Zhou K.L., Lou Y.Y., Pan D.Q., Shi J.H. Probing the behavior of bovine serum albumin upon binding to atenolol: insights from spectroscopic and molecular docking approaches. J. Biomol. Struct. Dyn. 2018;36:1095–1107. doi: 10.1080/07391102.2017.1311805. [DOI] [PubMed] [Google Scholar]
- Kandagal P., Ashoka S., Seetharamappa J., Shaikh S., Jadegoud Y., Ijare O. Study of the interaction of an anticancer drug with human and bovine serum albumin: spectroscopic approach. J. Pharm. Biomed. Anal. 2006;41:393–399. doi: 10.1016/j.jpba.2005.11.037. [DOI] [PubMed] [Google Scholar]
- Kim S.H., Hyun S.H., Choung S.Y. Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice. J. Ethnopharmacol. 2006;104:119–123. doi: 10.1016/j.jep.2005.08.059. [DOI] [PubMed] [Google Scholar]
- Krauss R.M. Atherogenicity of triglyceride-rich lipoproteins. Am. J. Cardiol. 1998;81:13B–17B. doi: 10.1016/s0002-9149(98)00032-0. [DOI] [PubMed] [Google Scholar]
- Lakowicz J.R. Kluwer Academic/Plenum Publishers; New York: 2004. Principles of Fluorescence Spectroscopy, (1999) [Google Scholar]
- Loyd J.B., Evett I.W. Prediction of peak wavelengths and intensities in synchronously excited fluorescence emission spectra. Anal. Chem. 1977;49:1710–1715. [Google Scholar]
- Mater, J.H., 2010. 175, 985–991.
- Mote U., Bhattar S., Patil S., Kolekar G. Interaction between felodipine and bovine serum albumin: fluorescence quenching study. Luminescence. 2010;25:1. doi: 10.1002/bio.1130. [DOI] [PubMed] [Google Scholar]
- Peters, T., 1996. Metabolism: albumin in the body. All About Albumin Biochemistry, Genetics, And Medical Applications.
- Rabbani G., Baig M.H., Jan A.T., Lee E.J., Khan M.V., Zaman M., Farouk A.E., Khan R.H., Choi I. Binding of erucic acid with human serum albumin using a spectroscopic and molecular docking study. Int. J. Biol. Macromol. 2017;105:1572–1580. doi: 10.1016/j.ijbiomac.2017.04.051. [DOI] [PubMed] [Google Scholar]
- Rabbani G., Khan M.J., Ahmad A., Maskat M.Y., Khan R.H. Effect of copper oxide nanoparticles on the conformation and activity of β-galactosidase. Colloids Surf. B Biointerf. 2014;123:96–105. doi: 10.1016/j.colsurfb.2014.08.035. [DOI] [PubMed] [Google Scholar]
- Rabbani G., Baig M.H., Lee E.J., Cho W.K., Ma J.Y., Choi I. Biophysical study on the interaction between eperisone hydrochloride and human serum albumin using spectroscopic, calorimetric, and molecular docking analyses. Mol. Pharm. 2017;14:1656–1665. doi: 10.1021/acs.molpharmaceut.6b01124. [DOI] [PubMed] [Google Scholar]
- Rabbani G., Lee E.J., Ahmad K., Baig M.H., Choi I. Binding of tolperisone hydrochloride with human serum albumin: effects on the conformation, thermodynamics, and activity of HSA. Mol. Pharm. 2018;15:1445–1456. doi: 10.1021/acs.molpharmaceut.7b00976. [DOI] [PubMed] [Google Scholar]
- Ross P.D., Subramanian S. Thermodynamics of protein association reactions: forces contributing to stability. Biochemistry. 1981;20:3096–3102. doi: 10.1021/bi00514a017. [DOI] [PubMed] [Google Scholar]
- Rubins H.B., Robins S.J. Conclusions from the VA-HIT study. Am. J. Cardiol. 2000;86:543–544. doi: 10.1016/s0002-9149(00)01010-9. [DOI] [PubMed] [Google Scholar]
- Rubins H.B. Triglycerides and coronary heart disease: implications of recent clinical trials. J. Cardiovasc. Risk. 2000;7:339–345. doi: 10.1177/204748730000700507. [DOI] [PubMed] [Google Scholar]
- Shi J.H., Zhou K.L., Lou Y.Y., Pan D.Q. Multi-spectroscopic and molecular modeling approaches to elucidate the binding interaction between bovine serum albumin and darunavir, a HIV protease inhibitor. Spectrochim. Acta. A Mol. Biomol. Spectrosc. 2018;188:362–371. doi: 10.1016/j.saa.2017.07.040. [DOI] [PubMed] [Google Scholar]
- Shi J.H., Lou Y.Y., Zhou K.L., Pan D.Q. Elucidation of intermolecular interaction of bovine serum albumin with Fenhexamid: a biophysical prospect. J. Photochem. Photobiol. B. 2018;1(180):125–133. doi: 10.1016/j.jphotobiol.2018.01.025. [DOI] [PubMed] [Google Scholar]
- Suryawanshi V.D., Walekar L.S., Gore A.H., Anbhule P.V., Kolekar G.B. Spectroscopic analysis on the binding interaction of biologically active pyrimidine derivative with bovine serum albumin. J. Pharm. Anal. 2016;6:56–63. doi: 10.1016/j.jpha.2015.07.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang Q., Huang C.R., Jiang M., Zhu Y.Y., Wang J., Chen J., Shi J.H. Binding interaction of atorvastatin with bovine serum albumin: spectroscopic methods and molecular docking. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2016;156:155–163. doi: 10.1016/j.saa.2015.12.003. [DOI] [PubMed] [Google Scholar]
- Wang Y.-Q., Zhang H.-M., Zhang G.-C., Tao W.-H., Fei Z.-H., Liu Z.-T. Spectroscopic studies on the interaction between silicotungstic acid and bovine serum albumin. J. Pharm. Biomed. Anal. 2007;43:1869–1875. doi: 10.1016/j.jpba.2007.01.001. [DOI] [PubMed] [Google Scholar]
- Wani T.A., AlRabiah H., Bakheit A.H., Kalam M.A., Zargar S. Study of binding interaction of rivaroxaban with bovine serum albumin using multi-spectroscopic and molecular docking approach. Chem. Cent. J. 2017;11:134. doi: 10.1186/s13065-017-0366-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wani T.A., Bakheit A.H., Abounassif M., Zargar S. Study of interactions of an anticancer drug neratinib with bovine serum albumin: spectroscopic and molecular docking approach. Front. Chem. 2018;6:47. doi: 10.3389/fchem.2018.00047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wani T.A., Bakheit A.H., Al-Majed A.-R.A., Bhat M.A., Zargar S. Study of the Interactions of Bovine Serum Albumin with the New Anti-Inflammatory Agent 4-(1, 3-Dioxo-1, 3-dihydro-2H-isoindol-2-yl)-N′-[(4-ethoxy-phenyl) methylidene] benzohydrazide using a multi-spectroscopic approach and molecular docking. Molecules. 2017;22:1258. doi: 10.3390/molecules22081258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wani T.A., Bakheit A.H., Ansari M.N., Al-Majed A.R.A., Al-Qahtani B.M., Zargar S. Spectroscopic and molecular modeling studies of binding interaction between bovine serum albumin and roflumilast. Drug Des., Dev. Therapy. 2018;12:2627–2634. doi: 10.2147/DDDT.S169697. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wani T.A., Bakheit A.H., Zargar S., Hamidaddin M.A., Darwish I.A. Spectrophotometric and molecular modelling studies on in vitro interaction of tyrosine kinase inhibitor linifanib with bovine serum albumin. PloS One. 2017;12 doi: 10.1371/journal.pone.0176015. e0176015.Z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ware W.R. Oxygen quenching of fluorescence in solution: an experimental study of the diffusion process. J. Phys. Chem. 1962;66:455–458. [Google Scholar]
- Zhao L., Liu R., Zhao X., Yang B., Gao C., Hao X., Wu Y. New strategy for the evaluation of CdTe quantum dot toxicity targeted to bovine serum albumin. Sci. Total Environ. 2009;407:5019–5023. doi: 10.1016/j.scitotenv.2009.05.052. [DOI] [PubMed] [Google Scholar]
- Zhang Y.F., Zhou K.L., Lou Y.Y., Pan D.Q., Shi J.H. Investigation of the binding interaction between estazolam and bovine serum albumin: multi-spectroscopic methods and molecular docking technique. J. Biomol. Struct. Dyn. 2017;35(16):3605–3614. doi: 10.1080/07391102.2016.1264889. [DOI] [PubMed] [Google Scholar]
- Zhao X., Liu R., Chi Z., Teng Y., Qin P. New insights into the behavior of bovine serum albumin adsorbed onto carbon nanotubes: comprehensive spectroscopic studies. J. Phys. Chem. B. 2010;114:5625–5631. doi: 10.1021/jp100903x. [DOI] [PubMed] [Google Scholar]
- Zhou K.L., Pan D.Q., Lou Y.Y., Shi J.H. Intermolecular interaction of fosinopril with bovine serum albumin (BSA): the multi-spectroscopic and computational investigation. J. Mol. Recognit. 2018;(16) doi: 10.1002/jmr.2716. [DOI] [PubMed] [Google Scholar]
- Zhu X., Sun J., Hu Y. Determination of protein by hydroxypropyl-β-cyclodextrin sensitized fluorescence quenching method with erythrosine sodium as a fluorescence probe. Anal Chim. Acta. 2007;596:298–302. doi: 10.1016/j.aca.2007.06.008. [DOI] [PubMed] [Google Scholar]
- Zimmet P., Alberti K., Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782. doi: 10.1038/414782a. [DOI] [PubMed] [Google Scholar]







